INS and breast cancer: A multicentric case–control study performed across 92 institutions in the UK, US, and Canada, including 775 women with DM diagnosed with breast cancer, found no significant risk difference between human insulin users and insulin glargine users (HR 1.29, 95% CI 0.78–2.13) [23].